nuclear receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
==== Acute myocardial infarction ==== Beta blockers are indicated for the treatment of acute myocardial infarctions. During a myocardial infarction, systemic stress causes an increase in circulating catecholamines. This results an increase in heart rate and blood pressure, therefore increasing myocardial oxygen demand. Beta blockers competitively inhibit catecholamines acting on the β1-adrenergic receptors, thus reducing these detrimental effects and resulting in reduced myocardial oxygen consumption and demand. A 2019 Cochrane review compared beta blockers with placebo or no intervention, it found that beta blockers probably reduced the short-term risk of reinfarction and the long-term risk of all-cause mortality and cardiovascular mortality. The review identified that beta blockers likely had little to no impact on short-term all-cause mortality and cardiovascular mortality.
Humira is also submitted for global regulatory approval for psoriasis (the fifth Humira disease indication). Humira achieved more than US$3 billion in worldwide Humira sales. 2007: Abbott opens new biotechnology manufacturing facility in Puerto Rico 2008: Humira made available as a treatment for plaque psoriasis 2009: Five-year data indicate that the initial use of Humira co-administered with methotrexate may prevent further joint damage in early rheumatoid arthritis patients 2012: Humira possibly associated with a significant decrease in vascular inflammation, a major risk factor of cardiovascular disease 2013: Due to the separation of Abbott's research-based pharmaceuticals business unit, AbbVie acquires the rights to Humira. 2014: Humira recognized by IMS Health as the "world's best selling drug". 2014: In December 2014, Indian drugmaker Cadila Healthcare (as of 2022, Zydus Pharmaceuticals) announced the first adalimumab biosimilar drug at a fifth of its American price. The generic was launched under the brand name Exemptia. 2015: Humira made available for moderate to severe hidradenitis suppurativa, an orphan indication. At the time, no other treatment had been rigorously tested and found to be safe and effective in treating Hurley Stage II and Hurley Stage III disease.
The military base was now ostensibly renamed for Roland L. Bragg, a previously obscure soldier who served in World War II. In a meeting before the Ukraine Defense Contact Group at NATO headquarters, he opposed NATO membership for Ukraine and said that returning Ukraine's borders prior to the annexation of Crimea by Russia was "unrealistic". The Department of Defense invited Jack Posobiec, an alt-right political activist to accompany Hegseth, according to The Washington Post. Hegseth moderated his comments the following day, stating that it would be possible for Ukraine to join NATO given Trump's discretion. In February 2025, Hegseth ordered officials within the Department of Defense to reduce funding on most initiatives and began a purge from within the department, firing three top judge advocate generals and Lisa Franchetti, the chief of naval operations. Hegseth stated that "we want lawyers who give sound constitutional advice" rather than "roadblocks to anything". In March, he ordered US Cyber Command to halt offensive operations against Russia, in an apparent effort to encourage Russian president Vladimir Putin to negotiate an end to the Russo-Ukrainian War.
==== School of Global Journalism and Communication ==== Established in 2013, Morgan's School of Global Journalism and Communication is one of only two Maryland-based universities with an internationally accredited journalism school. The School of Global Journalism and Communication degree programs include journalism, strategic communications, and multiplatform production. The programs are accredited by the Accrediting Council on Education in Journalism and Mass Communications (ACEJMC), as recognized by the Association for Education in Journalism and Mass Communication (AEJMC). The school is also the host of the student-run newspaper The Spokesman, the university's radio station WMUR Baltimore, and its television network BEAR-TV.
Sources: en.wikipedia.org
McGregor starred in Moulin Rouge! (2001) as the young poet Christian, who falls in love with the terminally-ill courtesan Satine (Nicole Kidman), for which his performance was widely praised and garnered McGregor his first Golden Globe Award for Best Actor – Motion Picture Musical or Comedy nomination. He also appeared in Ridley Scott's war film Black Hawk Down (2001) as John Grimes. He starred alongside Renée Zellweger in Down with Love (2003). He also portrayed the younger Edward Bloom in Tim Burton's critically acclaimed film Big Fish (2003) alongside Albert Finney, Jessica Lange, Alison Lohman and Billy Crudup. In the same period, he also received critical acclaim for his portrayal of an amoral drifter mixed up with murder in the drama Young Adam (also 2003), which co-starred Tilda Swinton. McGregor voiced the robot Rodney Copperbottom in Robots and the lead character in Gary Chapman's Valiant (both 2005). Also around this time, McGregor played two roles – one a clone of the other – opposite Scarlett Johansson in Michael Bay's science fiction action thriller film The Island (2005). He also headlined Marc Forster's 2005 film Stay, a psychological thriller co-starring Naomi Watts and Ryan Gosling.
=== Metabolic modulation === Bemethyl also has a positive effect on metabolic processes, allowing adaptation to conditions causing frequent hypoxia, and the obtained effect is long-lasting and also occurs after the end of dosage.
== Awards == In 2004 the ELGA CENTRA received an Industrial Product Design Award; in 2009 the PURELAB Ultra was the Readers Choice Laboratory Equipment winner: the ELGA PURELAB flex received the Instrument Business Outlook (IBO) Silver design award for Laboratory Equipment Industrial Design in 2009, the Aquatech China Innovation Gold Award in 2010 and the Industrial Product Design Gold Award, the Materials Innovation Gold Award, the dBA Design Effectiveness and the Red Dot Award in 2011; in 2011 the ELGA PURELAB Pulse also received the Scientists Choice Award.
Tandem mass spectrometry (MS/MS) is used to measure fragmentation spectra and identify proteins at high speed and accuracy. Collision-induced dissociation is used in mainstream applications to generate a set of fragments from a specific peptide ion. The fragmentation process primarily gives rise to cleavage products that break along peptide bonds. Because of this simplicity in fragmentation, it is possible to use the observed fragment masses to match with a database of predicted masses for one of many given peptide sequences. Tandem MS of whole protein ions has been investigated recently using electron capture dissociation and has demonstrated extensive sequence information in principle but is not in common practice.
The above discussion is based on the ideal vapour-compression refrigeration cycle, and does not take into account real-world effects like frictional pressure drop in the system, slight thermodynamic irreversibility during the compression of the refrigerant vapor, or non-ideal gas behavior, if any. Vapor compression refrigerators can be arranged in two stages in cascade refrigeration systems, with the second stage cooling the condenser of the first stage. This can be used for achieving very low temperatures. More information about the design and performance of vapor-compression refrigeration systems is available in the classic Perry's Chemical Engineers' Handbook.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.